Evidence map›Paper›PMID 41326423›Full record

ArticleNPJ Parkinson's disease2025

Quantification of cerebrospinal fluid α-synuclein seeds by endpoint dilution seed amplification assay in Parkinson's disease.

Kathrin Brockmann, Alice Ticca, Stefanie Lerche, Andrea Mastrangelo, Angela Mammana, Isabel Wurster, Erica Vittoriosi, Benjamin Roeben, Ann-Kathrin Hauser, Christian Deuschle and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kathrin Brockmann *Department of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Alice Ticca *IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Stefanie LercheDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Andrea MastrangeloIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Angela MammanaIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Isabel WursterDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Erica VittoriosiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Benjamin RoebenDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Ann-Kathrin HauserDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Christian DeuschleDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Simone BaiardiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Claudia SchulteDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Thomas GasserDepartment of Neurodegeneration, Center of Neurology, Hertie Institute for Clinical Brain Research, German Center for Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.
Piero ParchiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. piero.parchi@unibo.it.

Funding

Deutsches Zentrum für Neurodegenerative Erkrankungen MIGAP studyGerman Federal Ministry of Education and Research FKZ 031L0137BGerman Federal Ministry of Education and Research PD dementiaMinistero della Salute Ricerca Corrente
6 · The paper itself

Abstract

Quantitative pathology-specific biomarkers are needed for patients with Parkinson's disease (PD). We estimated the α-syn seeding dose giving 50% of positive seed amplification assay (SAA) reactions (SD50) in serially diluted samples from 260 PD participants, of whom 54 had longitudinal samples. We then evaluated the associations between SD50 values and demographic and clinical parameters, including motor and cognitive scales, REM sleep behaviour disorder (RBD), and hyposmia. Higher SD50 values were significantly associated with older age, longer disease duration, worse motor and cognitive scores, and presence of RBD and visual hallucinations. Baseline SD50 values predicted the development of motor wearing-off and severe cognitive impairment. In participants with longitudinal samples, SD50 values remained substantially stable over time. Quantification of α-syn through endpoint dilution SAA may serve as a potential surrogate marker of LB pathological burden, which may support prognostication and patient stratification.

Identifiers

PMID41326423
PMCPMC12775113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.